JP2004501870A5 - - Google Patents

Download PDF

Info

Publication number
JP2004501870A5
JP2004501870A5 JP2001579823A JP2001579823A JP2004501870A5 JP 2004501870 A5 JP2004501870 A5 JP 2004501870A5 JP 2001579823 A JP2001579823 A JP 2001579823A JP 2001579823 A JP2001579823 A JP 2001579823A JP 2004501870 A5 JP2004501870 A5 JP 2004501870A5
Authority
JP
Japan
Prior art keywords
hcl
antitumor
composition
acetate
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001579823A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004501870A (ja
Filing date
Publication date
Priority claimed from US09/561,917 external-priority patent/US6462017B1/en
Application filed filed Critical
Publication of JP2004501870A publication Critical patent/JP2004501870A/ja
Publication of JP2004501870A5 publication Critical patent/JP2004501870A5/ja
Pending legal-status Critical Current

Links

JP2001579823A 2000-05-01 2001-04-19 ガン患者における化学療法の副作用を軽減させる方法 Pending JP2004501870A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/561,917 US6462017B1 (en) 2000-05-01 2000-05-01 Method of reducing side effects of chemotherapy in cancer patients
PCT/US2001/012696 WO2001082949A2 (en) 2000-05-01 2001-04-19 Method of reducing side effects of chemotherapy in cancer patients

Publications (2)

Publication Number Publication Date
JP2004501870A JP2004501870A (ja) 2004-01-22
JP2004501870A5 true JP2004501870A5 (cg-RX-API-DMAC7.html) 2005-07-07

Family

ID=24244042

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001579823A Pending JP2004501870A (ja) 2000-05-01 2001-04-19 ガン患者における化学療法の副作用を軽減させる方法

Country Status (9)

Country Link
US (1) US6462017B1 (cg-RX-API-DMAC7.html)
EP (1) EP1357935B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004501870A (cg-RX-API-DMAC7.html)
CN (1) CN100441221C (cg-RX-API-DMAC7.html)
AT (1) ATE348630T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001255475B2 (cg-RX-API-DMAC7.html)
CA (1) CA2407238C (cg-RX-API-DMAC7.html)
DE (1) DE60125417D1 (cg-RX-API-DMAC7.html)
WO (1) WO2001082949A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE554756T1 (de) * 2001-03-14 2012-05-15 Bristol Myers Squibb Co Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
UA77999C2 (en) * 2001-12-10 2007-02-15 Thymosin-alpha 1 for treatment of malignant glioblastoma
KR20050086819A (ko) * 2002-11-25 2005-08-30 시클론 파마수티컬 인코포레이티드 알파 티모신을 사용한 방사능 손상에 대한 보호방법
JP2006213645A (ja) * 2005-02-03 2006-08-17 Hokkaido Univ ゲラニルゲラニルアセトンと抗癌剤とを組み合わせてなる医薬
JP5044150B2 (ja) * 2005-08-05 2012-10-10 Ｔｏｔｏ株式会社 光照射により薬効を消失させる医薬二酸化チタン複合材
US8017129B2 (en) * 2006-06-15 2011-09-13 SciClone Pharmaceuticals International Ltd Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
US20070292392A1 (en) * 2006-06-15 2007-12-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma
US20080253997A1 (en) * 2007-03-27 2008-10-16 Perscitus Biosciences, Llc Compositions and methods for protecting cells from toxic exposures
US20080300166A1 (en) * 2007-06-01 2008-12-04 Sciclone Pharmaceuticals, Inc. Treatment of Melanoma with Alpha Thymosin Peptides
JP2011506467A (ja) * 2007-12-14 2011-03-03 サイクローン・ファーマシューティカルズ・インコーポレイテッド 抗悪性腫瘍性熱ショックアポトーシス活性化因子（ｈｓａａ）と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
CA2753844A1 (en) * 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies
WO2012109106A1 (en) * 2011-02-09 2012-08-16 Sciclone Pharmaceuticals, Inc. Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
US20140322320A1 (en) * 2013-04-24 2014-10-30 Uday Saxena Novel compositions for emesis control in cancer patients undergoing chemotherapy and methods thereof
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
RU2726131C2 (ru) 2015-05-22 2020-07-09 Дмитрий Дмитриевич Генкин Внеклеточная днк в качестве терапевтической мишени при нейродегенерации
CA3001543C (en) * 2015-10-29 2023-06-27 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
CN107137684A (zh) * 2017-05-23 2017-09-08 山西中医学院 一种用于胃肠疾病的药物组合物及其制备方法和用途
FR3074042A1 (fr) 2017-11-29 2019-05-31 Galderma Research & Development Kit pour son utilisation dans la prevention et/ou le traitement des effets secondaires lies a une therapie anticancereuse
EP3740581A4 (en) 2018-01-16 2021-10-27 CLS Therapeutics Limited TREATMENT OF DISEASES BY LIVER EXPRESSION OF AN ENZYME WITH DESOXYRIBONUCLEASE (DNASE) ACTIVITY
CN109820859A (zh) * 2019-04-09 2019-05-31 上海市计划生育科学研究所 醋酸诺美孕酮在制备预防或治疗呕吐或改善恶病质的药物中的应用
IT202300020361A1 (it) 2023-10-03 2025-04-03 Blue Hydrogen Science S R L Nuovi utilizzi di soluzioni acquose ad elevata concentrazione di idrogeno

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US527393A (en) * 1894-10-09 Busy-test for multiple switchboards
US5273963A (en) 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide

Similar Documents

Publication Publication Date Title
CA2407238A1 (en) The use of thymosin alpha 1 to reduce the side effects of chemotherapy in cancer patients
CN104818414B (zh) 一种具有多孔结构的金属植骨材料及其制备和应用
DE3007446A1 (de) Element zur implantation in koerpergewebe
CN111155013B (zh) 一种医用三维打印合金材料及其制备方法
JP2017519753A5 (cg-RX-API-DMAC7.html)
RU2008117295A (ru) Новые пиразолопиримидины как ингибиторы циклинзависимых киназ
CN111195374A (zh) 一种具有骨诱导活性的医用可降解镁-锌-镁复合棒材及其制备方法
PE44799A1 (es) Antagonistas del receptor de vitronectina
HU0201043D0 (cg-RX-API-DMAC7.html)
Chen et al. Biodegradable Zinc‐Based Alloys for Guided Bone Regeneration Membranes: Feasibility, Current Status, and Future Prospects
AU2001255475A1 (en) Method of reducing side effects of chemotherapy in cancer patients
AU2001255475A2 (en) Method of reducing side effects of chemotherapy in cancer patients
CN104762542A (zh) 生物医用可降解吸收Mg-Sr-Cu合金材料及制备方法和应用
JP2023145674A5 (cg-RX-API-DMAC7.html)
JP2005508322A5 (cg-RX-API-DMAC7.html)
DE3206726A1 (de) Pharmakadepot
NZ223720A (en) Dsrna/lymphokine therapy optionally using cyclooxygenase activator to increase the levels of nk (natural killer) and lak (lymphokine activated killer) cells
CA2461227A1 (en) Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
CN104511051B (zh) 一种预防和治疗骨感染的复合骨水泥及其制备方法
Grevstad et al. Effect of doxycycline on surgically induced osteoclast recruitment in the rat
De Vos et al. Paclitaxel and carboplatin concurrent with radiotherapy for primary cervical cancer
US11345981B2 (en) Biodegradable metal alloy with multiple properties
EP1066065A1 (de) Bio-zemente mit verbesserten eigenschaften
JP2008222506A (ja) 生物学的活性物質含有リン酸八カルシウム系結晶、その製造方法及びそれを含む医薬組成物
IL299673A (en) Anticancer activity of paraborate salts